Euro-HSP is pleased to announce that the Adolf Struempell Prize 2025 will be awarded to Mrs. Alzhraa A. Ibrahim, PhD from the University Hospital Erlangen, Germany for her Paper entitled “Mobile digital gait analysis captures effects of botulinum toxin in hereditary spastic paraplegia,” European Journal of Neurology 31 (2024). The prize will be presented at the Tom Wahlig Symposium in Heidelberg, Germany on March 14.
The paper was selected based on the scores of an international expert jury. Euro-HSP wants to thank the winner for accomplishing such important work. By enrolling a genetically heterogeneous and impressively large cohort of 56 patients at three study centers, the investigations provide evidence for the beneficial effects of botulinum toxin in HSP, when applied according to individual treatment goals. Results displayed significant correlations between objective gait parameters and clinical scores.
From the perspective of Euro-HSP this trial investigating the benefit of a symptomatic treatment approach generates significant valuable experience for designing future trials on causal therapies. Euro-HSP expresses its gratitude to all applicants and in particular to these year’s winner for their important work on improvement of clinical HSP-management.
Dr. Ibrahim graduated in Computer Science from the Assiut University, Egypt. In 2024, she received her Ph.D. in Artificial Intelligence in Biomedical Engineering from the Technical Faculty at FAU Erlangen-Nürnberg. Her recent research explores gait impairments in hereditary spastic paraplegia (HSP) and other movement disorders, using digital gait analysis and predictive modeling to enhance clinical decision-making. With the motivation to overcome challenges and inspire future generations, she successfully balanced her academic journey while raising two young children alone, showcasing her resilience and commitment to advancing digital health research.
Euro-HSP thanks the Tom Wahlig Foundation for the excellent co-operation. We are looking forward to awarding Dr. Ibrahim at the Tom Wahlig Symposium 2025 in Heidelberg, Germany.
